title: Landiolol reduces coronary artery motion in an open-chest porcine model: implications for off-pump coronary artery bypass surgery.
abstract: Reduction of target coronary artery motion is imperative for successful off-pump coronary artery bypass surgery. We hypothesized that landiolol, a novel ultra-short-acting selective β-1 blocker, would reduce such coronary artery motion. To test this hypothesis, the motion of the left anterior descending artery of the porcine heart (n = 8) was analyzed by three-dimensional digital motion capture and reconstruction technology with or without continuous landiolol infusion. Landiolol (0.12 mg/kg/min) significantly decreased the heart rate (105 ± 16 vs. 90 ± 9 beats/min), three-dimensional distance moved (-20.4% vs. control), maximum velocity (-30.0% vs. control), acceleration (-31.1% vs. control), and deceleration (-28.6% vs. control) without inducing a significant change in the systolic blood pressure (85 ± 18 vs. 81 ± 22 mmHg), cardiac output (4.3 ± 1.4 vs. 4.1 ± 1.3 l/min), or pulmonary wedge pressure (7.8 ± 3.0 vs. 8.7 ± 2.9 mmHg). Landiolol reduces the heart rate and coronary artery motion with stable hemodynamics, which may facilitate performing precise anastomosis on the beating heart.
authors: Department of Cardiovascular Surgery, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. fukushima.cvsurg@gmail.com
authors: Hiroki
authors: H
authors: Wakamatsu
authors: Toshiki
authors: T
authors: Watanabe
authors: Yoshiyuki
authors: Y
authors: Sato
authors: Shinya
authors: S
authors: Takase
authors: Sadao
authors: S
authors: Omata
authors: Hitoshi
authors: H
authors: Yokoyama
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000818:Animals; D047549:Coronary Artery Bypass, Off-Pump / Q000379:methods*; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000601:surgery; D003331:Coronary Vessels / Q000187:drug effects / Q000503:physiopathology*; D004195:Disease Models, Animal; D005260:Female; D021621:Imaging, Three-Dimensional; D007262:Infusions, Intravenous; D009025:Morpholines / Q000008:administration & dosage*; D009200:Myocardial Contraction / Q000187:drug effects; D013552:Swine; D013908:Thoracotomy / Q000379:methods*; D014508:Urea / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea